"52" . "481925" . . . "\u017D\u00E1dn\u00E9 studie o u\u017E\u00EDv\u00E1n\u00ED imatinibu se anagrelid v BP nebyly nalezena. Jedenapades\u00E1tilety evropan s CML v blastick\u00E9 f\u00E1zi byl sledov\u00E1n po dobu 4 let. Imatinib mesyl\u00E1t v d\u00E1vce 600 mg p.o. QD. byl pod\u00E1v\u00E1n po ne\u00FAsp\u011Bchu na \u00FAvodn\u00ED chemoterapii. Pacient byl l\u00E9\u010Den imatinibem po dobu 45 m\u011Bs\u00EDc\u016F a 14,5 m\u011Bs\u00EDc\u016F v kombinaci s anagrelidem. \u010C\u00E1ste\u010Dn\u00E1 hematologick\u00E1 reakce v trv\u00E1n\u00ED 33 m\u011Bs\u00EDc\u016F byla indukov\u00E1na imatinibem, cytogenetick\u00E9 odpov\u011Bi nebylo dosa\u017Eeno. Imatinib-rezistentn\u00ED trombocytemie byla l\u00E9\u010Dena anagrelidem v d\u00E1vce 0.5-1 mg p.o. qd. \u017D\u00E1dn\u00E9 trombohemoragick\u00E9 komplikace nebyly pozorov\u00E1ny. Pacient sn\u00E1\u0161el kombinace imatinibu a anagrelidu dob\u0159e a dlouh\u00E1 doba p\u0159e\u017Eit\u00ED mu dala mo\u017Enost l\u00E9\u010Dby nov\u00FDm tyrosinkin\u00E1za inhibitorem (dasatinib)." . "CZ - \u010Cesk\u00E1 republika" . . . "[C4A87E9080F8]" . . "Kombinace imatinibu s anagrelidem v l\u00E9\u010Db\u011B blastick\u00E9ho zvratu chronick\u00E9 myeloidn\u00ED leukemie" . "Ber\u00E1nek, Martin" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . . "11150" . . "Kombinace imatinibu s anagrelidem v l\u00E9\u010Db\u011B blastick\u00E9ho zvratu chronick\u00E9 myeloidn\u00ED leukemie"@cs . "3"^^ . . . . . "4"^^ . . "Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase"@en . "S" . . "\u017D\u00E1dn\u00E9 studie o u\u017E\u00EDv\u00E1n\u00ED imatinibu se anagrelid v BP nebyly nalezena. Jedenapades\u00E1tilety evropan s CML v blastick\u00E9 f\u00E1zi byl sledov\u00E1n po dobu 4 let. Imatinib mesyl\u00E1t v d\u00E1vce 600 mg p.o. QD. byl pod\u00E1v\u00E1n po ne\u00FAsp\u011Bchu na \u00FAvodn\u00ED chemoterapii. Pacient byl l\u00E9\u010Den imatinibem po dobu 45 m\u011Bs\u00EDc\u016F a 14,5 m\u011Bs\u00EDc\u016F v kombinaci s anagrelidem. \u010C\u00E1ste\u010Dn\u00E1 hematologick\u00E1 reakce v trv\u00E1n\u00ED 33 m\u011Bs\u00EDc\u016F byla indukov\u00E1na imatinibem, cytogenetick\u00E9 odpov\u011Bi nebylo dosa\u017Eeno. Imatinib-rezistentn\u00ED trombocytemie byla l\u00E9\u010Dena anagrelidem v d\u00E1vce 0.5-1 mg p.o. qd. \u017D\u00E1dn\u00E9 trombohemoragick\u00E9 komplikace nebyly pozorov\u00E1ny. Pacient sn\u00E1\u0161el kombinace imatinibu a anagrelidu dob\u0159e a dlouh\u00E1 doba p\u0159e\u017Eit\u00ED mu dala mo\u017Enost l\u00E9\u010Dby nov\u00FDm tyrosinkin\u00E1za inhibitorem (dasatinib)."@cs . "4"^^ . "RIV/00216208:11150/06:00005008" . "Maisnar, Vladim\u00EDr" . . . . "Combination; imatinib; anagrelide; treatment; chronic; myeloid; leukemia; blastic; phase"@en . . . "RIV/00216208:11150/06:00005008!RIV08-MSM-11150___" . "0042-773X" . . "Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase"@en . "No study about the use of imatinib with anagrelide in BP has been found. 51-year-old white man with CML presented in blast phase was followed for 4 years. Imatinib mesylate in dose of 600 mg p.o. qd. was administered after the failure of initial chemotherapy. The patient was treated with imatinib for 45 months, 14.5 months in combination with anagrelide. Partial hematologic response in duration of 33 months was induced by imatinib, cytogenetic response was not reached. Imatinib-resistant thrombocythemia was controlled with anagrelide in dose of 0.5-1 mg p.o. qd. No thrombohemorrhagic complications were observed. The patient tolerated the combination of imatinib and anagrelide well and long-term survival gave him the chance of treatment with the new tyrosin kinase inhibitor (dasatinib)."@en . "Kombinace imatinibu s anagrelidem v l\u00E9\u010Db\u011B blastick\u00E9ho zvratu chronick\u00E9 myeloidn\u00ED leukemie"@cs . . . "9" . "819;822" . "Kombinace imatinibu s anagrelidem v l\u00E9\u010Db\u011B blastick\u00E9ho zvratu chronick\u00E9 myeloidn\u00ED leukemie" . . "Chrob\u00E1k, Ladislav" .